Home    Back

Raav2.5-cmv-minidystrophin (d3990)    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
113Muscular dystrophy1

113. Muscular dystrophy    [ 567 clinical trials,   442 drugs,   (DrugBank: 93 drugs),   55 drug target genes,   151 drug target pathways]
Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 567 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00428935
(ClinicalTrials.gov)		March 200626/1/2007Safety Study of Mini-dystrophin Gene to Treat Duchenne Muscular DystrophyPhase 1 Clinical Trial of rAAV2.5-CMV-mini-Dystrophin Gene Vector in Duchenne Muscular DystrophyDuchenne Muscular DystrophyBiological: rAAV2.5-CMV-minidystrophin (d3990)Nationwide Children's HospitalAsklepios Biopharmaceutical, Inc.Completed5 Years15 YearsMale6Phase 1United States